ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Tagworks Pharmaceuticals, a spin-off of Philips Healthcare, has raised $65 million in series A financing for its click-to-release therapies. The Dutch firm releases a therapeutic payload from a targeting molecule using a click reaction with a trigger molecule. Its lead program is an antibody-drug conjugate (ADC) that can be cleaved with click chemistry and targets a tumor-associated glycoprotein. The drug is made to allow a fine-tuned release and activation of the drug payload. Tagwork’s pipeline also contains ADCs and radiopharmaceuticals in the discovery phase.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter